Immage Biotherapeutics Corp. Stocks

$ 0Last Updated 13.02.2026

Issuer Rating

2/7

Performance

Average

Risk

Critical

Recommendation

Sell

Market Cap

$ 15174

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0
Key Takeaways

Risk factor

Critical default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Immage Biotherapeutics Corp. does not have significant business operations. Previously, it was engaged in developing novel immunotherapy biologics to treat various cancers in the United States. The company was formerly known as Epicure Charcoal, Inc. and changed its name to Immage Biotherapeutics Corp. in June 2015. The company was founded in 2012 and is headquartered...

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is 'cheap' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks